Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2

Katherine Davies; Ulrike Arnold; Hubert Buczkowski; Christopher Burton; Stephen R. Welch; Nicole Green; Rhea Strachan; Tracy Beetar-King; Peter Spencer; Nipunadi Hettiarachchi; Matthew J. Hannah; Matthew Jones; Patricia A. Cane; Christine B. Bruce; Neil Woodford; Allen D. G. Roberts; Marian J. Killip

doi:10.1038/s41598-021-02942-4

Scientific Reports (Dec 2021)

Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2

Katherine Davies,
Ulrike Arnold,
Hubert Buczkowski,
Christopher Burton,
Stephen R. Welch,
Nicole Green,
Rhea Strachan,
Tracy Beetar-King,
Peter Spencer,
Nipunadi Hettiarachchi,
Matthew J. Hannah,
Matthew Jones,
Patricia A. Cane,
Christine B. Bruce,
Neil Woodford,
Allen D. G. Roberts,
Marian J. Killip

Affiliations

Katherine Davies: High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England
Ulrike Arnold: High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England
Hubert Buczkowski: High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England
Christopher Burton: High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England
Stephen R. Welch: High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England
Nicole Green: High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England
Rhea Strachan: High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England
Tracy Beetar-King: High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England
Peter Spencer: High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England
Nipunadi Hettiarachchi: High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England
Matthew J. Hannah: High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England
Matthew Jones: High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England
Patricia A. Cane: High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England
Christine B. Bruce: High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England
Neil Woodford: NIS Laboratories, National Infection Service, Public Health England
Allen D. G. Roberts: High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England
Marian J. Killip: High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England

DOI: https://doi.org/10.1038/s41598-021-02942-4
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 7

Abstract

Read online

Abstract A pathogen inactivation step during collection or processing of clinical samples has the potential to reduce infectious risks associated with diagnostic procedures. It is essential that these inactivation methods are demonstrated to be effective, particularly for non-traditional inactivation reagents or for commercial products where the chemical composition is undisclosed. This study assessed inactivation effectiveness of twenty-four next-generation (guanidine-free) nucleic acid extraction lysis buffers and twelve rapid antigen test buffers against SARS-CoV-2, the causative agent of COVID-19. These data have significant safety implications for SARS-CoV-2 diagnostic testing and support the design and evidence-based risk assessment of these procedures.

Published in Scientific Reports

ISSN: 2045-2322 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Medicine; Science
Website: https://www.nature.com/srep/

About the journal